Scholarlink

In this chapter, the clinical use of 225Ac-PSMA will be discussed. This review describes the clinical history of alpha-emitting PSMA in treating mCRPC. Here, the potential, current status, and opportunities for 225Ac-PSMA therapy are presented. The work reviews the basic concepts, current treatment outcome, and toxicity and areas requiring further investigations such as dosimetric aspects in clinical studies covering more than 1000 patients. In general, approximately two-thirds of the patients benefit from this third-line therapy. There is also successful evidence of using 225Ac-PSMA in the second-line of prostate cancer management. The future potential of 225Ac-PSMA therapy and targeted alpha therapy of cancer in general is enormous. According to the clinical experience with 225Ac-PSMA therapy to date has shown great benefit and physicians dedicated to theragnostics are anxiously waiting for new applications.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Experience in 225Ac-PSMA

  • 章节

  • 发表日期：

    2025年

查看全文
  • Kalevi Kairemo

摘要

In this chapter, the clinical use of 225Ac-PSMA will be discussed. This review describes the clinical history of alpha-emitting PSMA in treating mCRPC. Here, the potential, current status, and opportunities for 225Ac-PSMA therapy are presented. The work reviews the basic concepts, current treatment outcome, and toxicity and areas requiring further investigations such as dosimetric aspects in clinical studies covering more than 1000 patients. In general, approximately two-thirds of the patients benefit from this third-line therapy. There is also successful evidence of using 225Ac-PSMA in the second-line of prostate cancer management. The future potential of 225Ac-PSMA therapy and targeted alpha therapy of cancer in general is enormous. According to the clinical experience with 225Ac-PSMA therapy to date has shown great benefit and physicians dedicated to theragnostics are anxiously waiting for new applications.